Margins were so narrow ...pretty difficult to what

Margins were so narrow ...pretty difficult to what if it in either direction. It was almost like they were one step behind from the get go. There was IMO a major complexion of cohort change from anecdotal to phase 3. I don’t believe that the FDA is actively trying to suppress CYDY any more than they are actively helping it. Obviously they will “put the part back in and see if it fails” for both haulers and 16. Clearly it works on HIV. I think minus cancer we all realize what the full gamut of efficacy may be for Leronlimab. The only questions left are:

1. What will it cost shareholders?
2. What will the reflection in SP be?
3. Going concern issues.
4. Buyout?

I think that covers it all unless someone can add or clarify.